CF
AKRO

Corebridge Financial’s Akero Therapeutics AKRO Stock Holding History

Corebridge Financial’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-36,523
Closed -$1.48M – 103
2025
Q1 		$1.48M Buy
36,523
+2,817
+8% +$119K 0.01% 1103
2024
Q4 		$938K Sell
33,706
-2,544
-7% -$77K 0.01% 1354
2024
Q3 		$1.04M Sell
36,250
-223
-0.6% -$5.81K 0.01% 1343
2024
Q2 		$856K Buy
+36,473
New +$780K ﹤0.01% 1410

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Corebridge Financial's AKRO Position: Q2 2025 in Review

Corebridge Financial sold out of Akero Therapeutics (AKRO) in Q2 2025, closing a stake of 36,523 shares — an estimated $1.48M sold.

Corebridge Financial first reported a position in AKRO in Q2 2024 and held it in 4 quarters. The position peaked at $1.48M in Q1 2025. 257 funds tracked by Wall St. Rank hold AKRO as of Q2 2025.

  • Corebridge Financial reported no remaining Akero Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 36,523 Akero Therapeutics shares in Q2 2025, an estimated $1.48M.
  • Corebridge Financial first reported a position in Akero Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Akero Therapeutics position peaked at $1.48M in Q1 2025.
  • 257 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.